RETROVIR IV FOR INFUSION Israel - English - Ministry of Health

retrovir iv for infusion

glaxo smith kline (israel) ltd - zidovudine - solution for infusion - zidovudine 200 mg / 20 ml - zidovudine - zidovudine - retrovir iv for infusion is indicated for the short term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immuno deficiency syndrome (aids) or aids who are unable to take retrovir oral formulations.retrovir chemoprophylaxis, is indicated for use in hiv-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal hiv transmission and for primary prophylaxis of hiv infection in newborn infants. retrovir i.v. should only be used when oral treatment is not possible (except during labour and delivery).

GRANOCYTE 34 Ireland - English - HPRA (Health Products Regulatory Authority)

granocyte 34

chugai pharma uk ltd - lenograstim - pdr+solv for soln for inf/inj - 34 million iu/ml

GRANOCYTE 34 34 million IU/ML Pdr+Solv for soln for inf/inj Ireland - English - HPRA (Health Products Regulatory Authority)

granocyte 34 34 million iu/ml pdr+solv for soln for inf/inj

chugai pharma uk ltd - lenograstim - pdr+solv for soln for inf/inj - 34 million iu/ml

Taxespira (previously Docetaxel Hospira UK Limited ) European Union - English - EMA (European Medicines Agency)

taxespira (previously docetaxel hospira uk limited )

hospira uk limited - docetaxel trihydrate - stomach neoplasms; prostatic neoplasms; breast neoplasms; head and neck neoplasms; carcinoma, non-small-cell lung - antineoplastic agents - breast cancertaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancer taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancer taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinoma taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancer taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

GRANOCYTE 34 million IU/mL, powder and solvent for solution for injection/infusion, in a pre-filled syringe Ireland - English - HPRA (Health Products Regulatory Authority)

granocyte 34 million iu/ml, powder and solvent for solution for injection/infusion, in a pre-filled syringe

chugai pharma france - lenograstim - powder and solvent for solution for injection/infusion - 34 million international unit(s)/millilitre - colony stimulating factors; lenograstim